# Alberto Chiappori

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alberto-chiappori/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,930 |
| Field | Lung Cancer Research Studies |
| h-index | 49 |
| i10-index | 105 |
| Last Known Institution | Moffitt Cancer Center |
| OpenAlex ID | https://openalex.org/A5080538468 |
| ORCID iD | 0000-0003-0810-7104 |
| Works | 257 |

## Researcher papers

Showing 12 of 15.

- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study](https://scholariq.org/papers/safety-and-activity-of-alectinib-against-systemic-disease-and-brain-metastases/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)
- [Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer](https://scholariq.org/papers/combination-of-p53-cancer-vaccine-with-chemotherapy-in-patients-with-extensive/)
- [Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC](https://scholariq.org/papers/three-year-overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii/)
- [Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial](https://scholariq.org/papers/tumor-infiltrating-lymphocyte-treatment-for-anti-pd-1-resistant-metastatic-lung/)
- [Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-double-blind-phase-ii-study-of-temozolomide-in-combination-with/)
- [Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer](https://scholariq.org/papers/therapeutic-regulation-of-myeloid-derived-suppressor-cells-and-immune-response/)
- [Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer](https://scholariq.org/papers/ensartinib-vs-crizotinib-for-patients-with-anaplastic-lymphoma-kinase-positive/)
- [Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pooled-analysis-of-cns-response-to-alectinib-in-two-studies-of-pretreated/)
- [Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-i-ii-study-of-the-src-inhibitor-dasatinib-in-combination-with-erlotinib-in/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Adenosine and Purinergic Signaling](https://scholariq.org/topics/adenosine-and-purinergic-signaling/)

## Researcher university

- [Moffitt Cancer Center](https://scholariq.org/institutions/moffitt-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.